Download PDF
Thromb Haemost 2018; 118(08): 1439-1449
DOI: 10.1055/s-0038-1667001
Stroke, Systemic or Venous Thromboembolism
Georg Thieme Verlag KG Stuttgart · New York

Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study

Noémie Kraaijpoel
1   Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
,
Marcello Di Nisio
2   Department of Medicine and Ageing Sciences, University G. D'Annunzio, Chieti, Italy
,
Frits I. Mulder
1   Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
,
Nick van Es
1   Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
,
Jan Beyer-Westendorf
3   Department of Medicine I, University Hospital Dresden, Dresden, Germany
,
Marc Carrier
4   Department of Medicine, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
,
David Garcia
5   Department of Hematology, University of Washington, Seattle, Washington, United States
,
Michael Grosso
6   Daiichi Sankyo Pharma Development, Basking Ridge, New Jersey, United States
,
Ajay K. Kakkar
7   Thrombosis Research Institute, University College London, London, United Kingdom
,
Michele F. Mercuri
6   Daiichi Sankyo Pharma Development, Basking Ridge, New Jersey, United States
,
Saskia Middeldorp
1   Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
,
Cristhiam Rojas Hernandez
8   MD Anderson Cancer Center, University of Texas, Houston, Texas, United States
,
Amparo Santamaria
9   Department of Hematology, University Hospital Vall d'Hebron, Barcelona, Spain
,
Lee Schwocho
6   Daiichi Sankyo Pharma Development, Basking Ridge, New Jersey, United States
,
Annelise Segers
10   ITREAS, Academic Research Organization, Amsterdam, The Netherlands
,
Peter Verhamme
11   University Hospitals Leuven, University of Leuven, Leuven, Belgium
,
Tzu-Fei Wang
12   The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
,
Jeffrey I. Weitz
13   Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, Ontario, Canada
,
George Zhang
6   Daiichi Sankyo Pharma Development, Basking Ridge, New Jersey, United States
,
Jeffrey I. Zwicker
14   Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States
,
Harry R. Büller
1   Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
,
Gary E. Raskob
15   University of Oklahoma Health Sciences Center, College of Public Health, University of Oklahoma, Oklahoma City, Oklahoma, United States
› Author Affiliations
Further Information

Publication History

09 April 2018

30 June 2018

Publication Date:
30 July 2018 (online)

    Permissions and Reprints

Abstract

In the Hokusai VTE Cancer study, edoxaban was non-inferior to dalteparin for the composite outcome of recurrent venous thromboembolism (VTE) and major bleeding in 1,050 patients with cancer-associated VTE. The absolute rate of recurrent VTE was 3.4% lower with edoxaban, whereas the absolute rate of major bleeding was 2.9% higher. The present analysis focuses on the sites, clinical presentation, course and outcome of bleeding events, and the associated tumour types. Major bleeds and their severity (categories 1–4) were blindly adjudicated by a committee using a priori defined criteria, and data were analysed in the safety population. Major bleeding occurred in 32 of 522 patients given edoxaban (median treatment duration, 211 days) and in 16 of 524 patients treated with dalteparin (median treatment duration, 184 days); no patients had more than one major bleed. There were no fatal bleeds with edoxaban, and two with dalteparin. Severe bleeding at presentation (category 3 or 4) occurred in 10 (1.9%) and 11 (2.1%) patients in the edoxaban and dalteparin groups, respectively. The excess of major bleeding with edoxaban was confined to patients with gastrointestinal cancer. However, severe major bleeding at presentation (category 3 or 4) in this sub-group occurred in 5 of 165 (3.0%) and in 3 of 140 (2.1%) patients given edoxaban or dalteparin, respectively.

In conclusion, this analysis suggests that while oral edoxaban is an appropriate alternative to subcutaneous dalteparin for treatment of cancer-associated VTE, the use of edoxaban in patients with gastrointestinal cancer requires careful benefit–risk weighting.

Keywords

venous thromboembolism - cancer - major bleeding - anticoagulant treatment - direct oral anticoagulants

Authors' Contributions

Study conception and design: N. Kraaijpoel, M. Di Nisio, M. Grosso, A. Segers, H.R. Büller and G.E. Raskob.


Data acquisition: M. Di Nisio, N. van Es, J. Beyer-Westendorf, M. Carrier, D. Garcia, M. Grosso, C. Rojas Hernandez, A. Santamaria, P. Verhamme, T.F. Wang and J.I. Zwicker.


Statistical analysis: G. Zhang.


Interpretation of the data: N. Kraaijpoel, M. Di Nisio, F.I. Mulder, N. van Es, J. Beyer-Westendorf, M. Carrier, D. Garcia, M. Grosso, A.K. Kakkar, M.F. Mercuri, S. Middeldorp, C. Rojas Hernandez, A. Santamaria, L. Schwocho, A. Segers, P. Verhamme, T.F. Wang, J.I. Weitz, G. Zhang, J.I. Zwicker, H.R. Büller and G.E. Raskob.


Drafting of the manuscript: N. Kraaijpoel, M. Di Nisio, F.I. Mulder, N. van Es, J. Beyer-Westendorf, M. Carrier, D. Garcia, M. Grosso, A.K. Kakkar, M.F. Mercuri, S. Middeldorp, C. Rojas Hernandez, A. Santamaria, L. Schwocho, A. Segers, P. Verhamme, T.F. Wang, J.I. Weitz, G. Zhang, J.I. Zwicker, H.R. Büller and G.E. Raskob.


Critical revision of the manuscript for important intellectual content: N. Kraaijpoel, M. Di Nisio, F.I. Mulder, N. van Es, J. Beyer-Westendorf, M. Carrier, D. Garcia, M. Grosso, A.K. Kakkar, M.F. Mercuri, S. Middeldorp, C. Rojas Hernandez, A. Santamaria, L. Schwocho, A. Segers, P. Verhamme, T.F. Wang, J.I. Weitz, G. Zhang, J.I. Zwicker, H.R. Büller and G.E. Raskob.


Final approval of the manuscript: N. Kraaijpoel, M. Di Nisio, F.I. Mulder, N. van Es, J. Beyer-Westendorf, M. Carrier, D. Garcia, M. Grosso, A.K. Kakkar, M.F. Mercuri, S. Middeldorp, C. Rojas Hernandez, A. Santamaria, L. Schwocho, A. Segers, P. Verhamme, T.F. Wang, J.I. Weitz, G. Zhang, J.I. Zwicker, H.R. Büller and G.E. Raskob.


 

  • References

  • 1 Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 2007; 5 (03) 632-634
    CrossrefPubMedGoogle Scholar
  • 2 Cohen AT, Katholing A, Rietbrock S, Bamber L, Martinez C. Epidemiology of first and recurrent venous thromboembolism in patients with active cancer. A population-based cohort study. Thromb Haemost 2017; 117 (01) 57-65
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Prandoni P, Lensing AW, Piccioli A. , et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002; 100 (10) 3484-3488
    CrossrefPubMedGoogle Scholar
  • 4 Mantha S, Ansell J. Indirect comparison of dabigatran, rivaroxaban, apixaban and edoxaban for the treatment of acute venous thromboembolism. J Thromb Thrombolysis 2015; 39 (02) 155-165
    CrossrefPubMedGoogle Scholar
  • 5 Khorana AA, Yannicelli D, McCrae KR. , et al. Evaluation of US prescription patterns: are treatment guidelines for cancer-associated venous thromboembolism being followed?. Thromb Res 2016; 145: 51-53
    CrossrefPubMedGoogle Scholar
  • 6 Bott-Kitslaar DM, Saadiq RA, McBane RD. , et al. Efficacy and safety of rivaroxaban in patients with venous thromboembolism and active malignancy: a single-center registry. Am J Med 2016; 129 (06) 615-619
    CrossrefPubMedGoogle Scholar
  • 7 Pignataro BS, Nishinari K, Cavalcante RN. , et al. Oral rivaroxaban for the treatment of symptomatic venous thromboembolism in 400 patients with active cancer: a single-center experience. Clin Appl Thromb Hemost 2017; 23 (07) 883-887
    CrossrefPubMedGoogle Scholar
  • 8 Theberge I, Bowdridge J, Forgie MA. , et al. Rivaroxaban shows promise as effective therapy for cancer patients with venous thromboembolic disease. Thromb Res 2017; 152: 4-6
    CrossrefPubMedGoogle Scholar
  • 9 Raskob GE, van Es N, Verhamme P. , et al; Hokusai VTE Cancer Investigators. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 2018; 378 (07) 615-624
    CrossrefPubMedGoogle Scholar
  • 10 Schulman S, Kearon C. ; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3 (04) 692-694
    CrossrefPubMedGoogle Scholar
  • 11 Bleker SM, Brekelmans MPA, Eerenberg ES. , et al. Clinical impact of major bleeding in patients with venous thromboembolism treated with factor Xa inhibitors or vitamin K antagonists. An individual patient data meta-analysis. Thromb Haemost 2017; 117 (10) 1944-1951
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 van Es N, Di Nisio M, Bleker SM. , et al. Edoxaban for treatment of venous thromboembolism in patients with cancer. Rationale and design of the Hokusai VTE-cancer study. Thromb Haemost 2015; 114 (06) 1268-1276
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Vanassche T, Hirsh J, Eikelboom JW, Ginsberg JS. Organ-specific bleeding patterns of anticoagulant therapy: lessons from clinical trials. Thromb Haemost 2014; 112 (05) 918-923
    Article in Thieme ConnectPubMedGoogle Scholar